Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, and Severe Juvenile Dermatomyositis

Trial Profile

Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, and Severe Juvenile Dermatomyositis

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Dermatomyositis; Skin disorders
  • Focus Expanded access; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 14 Nov 2017 Results of pooled data from two trial (NCT02974595 and NCT01724580) assessing pharmacokinetics, pharmacodynamics and oral dosing regimen of baricitinib in patients with rare interferonopathies, were published in the Clinical Pharmacology and Therapeutics.
    • 05 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top